| Name | Factor Xa |
|---|---|
| Synonyms | Coagulation factor X; F10; Fx; Coagulation factor X precursor; FXA; Factor Xa; Prothrombinase; Stuart factor… |
| Name | piperazine |
|---|---|
| CAS | piperazine |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 15056966 | Nishida H, Miyazaki Y, Mukaihira T, Shimada H, Suzuki K, Saitoh F, Mizuno M, Matsusue T, Okamoto A, Hosaka Y, Matsumoto M, Ohnishi S, Mochizuki H: Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Chem Pharm Bull. 2004 Apr;52(4):459-62. Compounds containing an ethylenediamine structure in place of the piperazine ring of M55113 (1) and M55551 (2) were synthesized to investigate the effects of a piperazine moiety and evaluated for activity as factor Xa (FXa) inhibitors. |
32(0,1,1,2) | Details |
| 15080981 | Jia ZJ, Su T, Zuckett JF, Wu Y, Goldman EA, Li W, Zhang P, Clizbe LA, Song Y, Bauer SM, Huang W, Woolfrey J, Sinha U, Arfsten AE, Hutchaleelaha A, Hollenbach SJ, Lambing JL, Scarborough RM, Zhu BY: N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors. Bioorg Med Chem Lett. 2004 May 3;14(9):2073-8. The strategy of incorporating a side chain on the piperazine nucleus to enhance binding affinity has been examined. |
3(0,0,0,3) | Details |
| 15456260 | Haginoya N, Kobayashi S, Komoriya S, Yoshino T, Suzuki M, Shimada T, Watanabe K, Hirokawa Y, Furugori T, Nagahara T: Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] as S4 binding element. J Med Chem. 2004 Oct 7;47(21):5167-82. |
2(0,0,0,2) | Details |
| 18507371 | Imaeda Y, Kuroita T, Sakamoto H, Kawamoto T, Tobisu M, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K: Discovery of imidazo [1,5-c] -3-ones: weakly basic, orally active factor Xa inhibitors. J Med Chem. 2008 Jun 26;51(12):3422-36. Epub 2008 May 29. To work out the pharmacokinetic problems, we focused our synthetic efforts on the chemical conversion of the 4-(imidazo [1,2- a] pyridin-5-yl) piperazine moiety of 1 to imidazolylpiperidine derivatives (fused and nonfused), which resulted in the discovery of the weakly basic imidazo [1,5- c] -3-one 3q as a potent and selective FXa inhibitor. |
2(0,0,0,2) | Details |
| 12593649 | Maignan S, Guilloteau JP, Choi-Sledeski YM, Becker MR, Ewing WR, Pauls HW, Spada AP, Mikol V: Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. J Med Chem. 2003 Feb 27;46(5):685-90. The scaffold comprising the sulfonyl keto piperazine moiety might play a pivotal role in the orientation of substituents, since there is a strong bond between Gly219 of fXa and the carbonyl of the piperazine. |
2(0,0,0,2) | Details |
| 17855089 | Shi Y, Sitkoff D, Zhang J, Han W, Hu Z, Stein PD, Wang Y, Kennedy LJ, O'Connor SP, Ahmad S, Liu EC, Seiler SM, Lam PY, Robl JA, Macor JE, Atwal KS, Zahler R: Amino (methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors. . Bioorg Med Chem Lett. 2007 Nov 1;17(21):5952-8. Epub 2007 Aug 21. The amino (methyl) pyrrolidine scaffolds were designed based on the proposed bioisosterism to the piperazine core in known FXa inhibitors. |
1(0,0,0,1) | Details |
| 12704411 | Johnson KJ, Peng KW, Allen C, Russell SJ, Galanis E: Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. Gene Ther. 2003 May;10(9):725-32. Use of the broad-spectrum MMP inhibitors, 1,10-phenanthroline and N--piperazine-carboxamide completely abolished the ability of MMP constructs to induce fusion. Expression constructs were made expressing the hyperfusogenic version of the Gibbon Ape Leukemia Virus envelope glycoprotein (GALV) linked to a blocking ligand (the C-terminal extracellular domain of CD40 ligand) via either an MMP cleavable linker (GALV M40), a factor Xa protease cleavable linker (GALV X40), or a noncleavable linker (GALV N40). |
1(0,0,0,1) | Details |
| 17555959 | Nagata T, Yoshino T, Haginoya N, Yoshikawa K, Isobe Y, Furugohri T, Kanno H: Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4683-8. Epub 2007 May 25. This paper describes the synthesis of orally available potent fXa inhibitors 2 and 3 by modification of the piperazine part of lead compound 1. |
1(0,0,0,1) | Details |